Not Yet RecruitingNot Applicable

Comparison of Liver Biopsy Versus Fibroscan With CAP ( Controlled Attenuation Parameter) in Donors Evaluation for Liver Transplant

100 participantsStarted 2026-07-01

Plain-language summary

In our study we aiming that liver biopsy histological analysis as a reference standard, to examine the precision of fbroscan controlled attenuation parameter (CAP) for quantitative evaluation of macrovesicular steatosis in living related liver donors.

Who can participate

Age range18 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * All donors aged \>18 years old * eligible for Liver Transplant Exclusion Criteria: * -Subjects aged ≤18 years old. * Donors refused to do FibroScan with CAP

What they're measuring

Diagnostic Accuracy of FibroScan Controlled Attenuation Parameter (CAP) for Quantitative Assessment of Macrovesicular Steatosis in Living Liver Donors: A Comparative Study with Liver Biopsy

Timeframe: 24 month

Trial details

NCT IDNCT07451379

SponsorAssiut University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-07-01

Contact for this trial

Amira M. Abdelmawgod, Lecturer, Tropical Medicine

+201012760437 amiramohmad60@gmail.com

View on ClinicalTrials.gov More Non-invasive Donor Liver Assessment trials